Medtronic (NYSE:MDT) today released results from two real-world analyses of its AdaptivCRT algorithm, touting that its use was linked to a reduction in atrial fibrillation episodes and higher patient activity levels.
Results from the analyses, which involved a total of 408 patients at 26 centers in Italy, were presented at the European Heart Rhythm Association’s Scientific Sessions 2018 in Barcelona, Spain, the company said.
Medtronic’s AdaptivCRT algorithm is designed to adjust pacing to the heart dependent upon evaluations of heart rhythm made every minute, the company said. The program has been shown to increase CRT response rate, reduce unnecessary ventricular pacing and improve clinical outcomes fro patients with normal av conduction in clinical trials.
“The AdaptivCRT feature continues to perform consistently in a variety of settings – the rigor of a randomized, controlled trial, as well as in real-world settings – and is associated with a significantly reduced risk of AF. Our broad portfolio of cardiac devices helps physicians detect, reduce, respond to and treat AF,” Medtronic VP & cardiac resynchronization therapy biz GM Dr. Kweli Thompson said in a press release.
In its first analysis, the Fridley, Minn.-based company said a significant reduction in AF episodes was observed in 210 patients with AdaptivCRT functionality turned on when compared to 198 patients with conventional CRT. The reduction was seen across all measured durations, ranging from one hour to seven days, Medtronic said.
“Atrial fibrillation is a common comorbidity among patients with heart failure. Progression of AF is linked to an increased risk of stroke and death, so it is encouraging to see additional clinical data that again links AdaptivCRT with a reduction in the incidence of AF in these patients,” Dr. Alessandro Proclemer of Udine, Italy’s University Hospital Santa Maria della Misericordia said in a prepared statement.
A second analysis indicated that use of the AdaptivCRT functionality was significantly and independently associated with higher daily activity when compared with patients treated with conventional CRT at 3.1 hours versus 2.6 hours, respectively.
“This finding is important since heart failure patients with low activity levels are more likely to be hospitalized, or even die. We want our patients to be as active as possible, given the seriousness of their heart condition,” Dr. Saverio Iacopino of Cotignola, Italy’s Maria Cecilia Hospital said in prepared remarks.
Yesterday, Medtronic touted results from a clinical trial of its Arctic Front Advance cryoballoon for treating atrial fibrillation.
